C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation (R), highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset ...
Early PrimeC treatment slowed functional decline and reduced the risk of death or ALS complications for ALS patients in a ...
CDNS expands NVDA tie-up to power agentic AI, boosting design speed, efficiency and enabling next-gen chip, system and even drug discovery innovation.
More than 80% of patients implanted with a transvenous phrenic nerve stimulation device for central sleep apnea had at least ...
The global wine industry spent two years in crisis. New data on drinking habits, a landmark EU trade deal, and hard-won pragmatism from producers suggest the worst may be over.
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate ...
Introduction Climate-sensitive mortality in rapidly urbanising tropical Africa is poorly characterised, and how pandemics disrupt established seasonal patterns remains underexplored. We analysed ...
Life Sciences / Bio: ROCS X is an AI-enabled virtual screening solution that enables scientists to conduct 3D searches of over 200 trillion drug-like molecules. Target X is a physics-based AI solution ...
Background: The factors involved in the association between obstetric trauma and the race of the birthing parent are uncertain. We sought to assess the association between race and obstetric trauma, ...
Delivers unified Synopsys-Ansys workflows that bring together previously separate engineering processes to create more cohesive and efficient product development ...
GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results